💊 Vitamin C Cancer Research

High-dose intravenous vitamin C has emerged as a topic of scientific interest in cancer research, distinct from the vitamin C found in dietary sources and oral supplements. Unlike standard oral vitamin C supplementation, intravenous administration allows researchers to achieve significantly higher concentrations in the bloodstream and potentially target cancer cells differently. This approach has attracted attention from both conventional oncologists and complementary medicine researchers seeking to understand whether vitamin C may play a supportive role in comprehensive cancer treatment plans.

The rationale behind studying high-dose IV vitamin C in cancer treatment stems from laboratory research suggesting that vitamin C may have selective effects on cancer cells while potentially supporting healthy immune function. Some preclinical studies have indicated that high concentrations of ascorbic acid could interfere with cancer cell metabolism and growth, though translating these findings to clinical benefit remains an active area of investigation. Current research explores how IV vitamin C might be integrated with conventional therapies, its safety profile in cancer patients, and which patient populations or cancer types may benefit most from this approach.

This page compiles the latest peer-reviewed research on high-dose intravenous vitamin C and cancer, providing patients, caregivers, and healthcare providers with evidence-based information about ongoing clinical trials, study results, and mechanisms of action. While vitamin C shows theoretical promise in laboratory settings, it is important to understand both the current evidence and the limitations of existing research. The articles below represent the most recent scientific findings on this supplement and nutraceutical approach to cancer care.